UNICREDIT BANK/PUT/BIOGEN IDEC/400/0.1/18.06.25 | Real-time BOERSE MUENCHEN 16:40:28 17/05/2024 BST | ||
| 15.77 EUR | +0.90% |
|
| Current month | -9.97% | ||
| 1 month | -18.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 15.77 | +0.90% |
| 16/05/24 | 15.63 | +3.03% |
| 15/05/24 | 15.17 | -5.19% |
| 14/05/24 | 16 | -1.48% |
| 13/05/24 | 16.24 | -1.16% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 04:40 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HC7N1L |
| ISIN | DE000HC7N1L8 |
| Date issued | 23/06/2023 |
| Strike | 400 $ |
| Maturity | 18/06/2025 (397 Days) |
| Parity | 10 : 1 |
| Emission price | 10.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.66 € |
|---|---|
| Lowest since issue | 10.17 € |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230
USD
Average target price
285.9
USD
Spread / Average Target
+24.29%
- Stock Market
- Warrants
- Warrant
